PharmaTher Holdings Ltd.

PHRM

CA71716H1082

PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is also commercializing PharmaPatch (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases.

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMATHER HOLDINGS LTD.	-33.33%	14.79M
ELI LILLY AND COMPANY	+28.10%	676B
NOVO NORDISK A/S	+24.27%	559B
JOHNSON & JOHNSON	-7.84%	356B
MERCK & CO., INC.	+14.71%	320B
ABBVIE INC.	+4.88%	286B
ASTRAZENECA PLC	+2.62%	213B
NOVARTIS AG	+0.15%	207B
ROCHE HOLDING AG	-9.41%	199B
AMGEN INC.	-7.77%	142B

Other Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 01:41:45 2024-04-16 pm EDT			5-day change	1st Jan Change
0.21 ^CAD	-8.70%		-12.50%	-33.33%

02:40pm	PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	MT
02:00pm	PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	CI

PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	08:40am	MT
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	08:00am	CI
PharmaTher Provides Update For PD-001	Feb. 21	MT
PharmaTher Provides Update on its Priority Original Abbreviated New Drug Application For Ketamine	Feb. 12	MT
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	Feb. 12	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	Jan. 26	CI
PharmaTher Provided Update for Expected FDA Approval of Ketamine	Jan. 10	MT
PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine	Jan. 10	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the First Quarter Ended August 31, 2023	23-10-30	CI
PharmaTher Holdings Ltd. Reports Earnings Results for the Full Year Ended May 31, 2023	23-09-28	CI
PharmaTher Announced FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for Ketarx	23-09-27	MT
PharmaTher Brief: Notes FDA assigns GDUFA goal date of April 29, 2024	23-09-27	MT
PharmaTher Brief: Announcing FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX (Ketamine)	23-09-27	MT
PharmaTher Holdings Ltd. Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX(TM)	23-09-27	CI
PharmaTher Submits Priority Original Abbreviated New Drug Application for Ketarx (Ketamine) to FDA	23-09-06	MT
PharmaTher Brief: Submitting Priority Original Abbreviated New Drug Application for KETARX (Ketamine) to FDA	23-09-06	MT
PharmaTher Holdings Ltd. Submits Priority Original Abbreviated New Drug Application for KETARX? to the FDA	23-09-06	CI
PharmaTher Reports "Positive" Research Results for PharmaPatch with DMT and Strategic Investment into Sairiyo Therapeutics	23-07-18	MT
PharmaTher Brief: Announcing "Positive" Research Results for PharmaPatch with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics	23-07-18	MT
PharmaTher Holdings Ltd. Announces Positive Research Results for PharmaPatch with N,N-Dymethyltryptamine and Strategic Investment into Sairiyo Therapeutics	23-07-18	CI
PharmaTher Files Abbreviated New Drug Application for Ketarx to FDA	23-06-27	MT
PharmaTher Holdings Ltd. Initiates Filing of Abbreviated New Drug Application for KETARX to the FDA	23-06-27	CI
PharmaTher and Vitruvias in Collaboration Agreement for Commercialization of Ketarx in the U.S.	23-06-20	MT
PharmaTher Holdings Ltd. and Vitruvias Therapeutics, Inc. Enter into Collaboration Agreement for Commercialization of KETARXâ„¢ (racemic ketamine) in the US	23-06-20	CI
PharmaTher Outlines Development and Commercialization Plans, Milestones for Ketarx and PharmaPatch Delivery System	23-06-12	MT

PharmaTher Holdings Ltd.

Equities

PHRM

CA71716H1082

Pharmaceuticals

Latest news about PharmaTher Holdings Ltd.

Chart PharmaTher Holdings Ltd.

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals